Citadel Advisors
NMTC icon

Citadel Advisors’s NeuroOne Medical Technologies NMTC Stock Holding History

Citadel Advisors’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,917
Closed -$78.8K – 14478
2026
Q1 		$78.8K Sell
16,917
-416
-2% -$2K ﹤0.01% 12183
2025
Q4 		$78.8K Buy
17,333
+13,750
+384% +$62.6K ﹤0.01% 11805
2025
Q3 		$19.1K Sell
3,583
-17,267
-83% -$84.5K ﹤0.01% 12496
2025
Q2 		$84.9K Buy
20,850
+9,250
+80% +$34.2K ﹤0.01% 11448
2025
Q1 		$59.2K Buy
11,600
+4,800
+71% +$30.5K ﹤0.01% 12131
2024
Q4 		$33.7K Buy
+6,800
New +$33.9K ﹤0.01% 12764
2024
Q1 		– Sell
-2,467
Closed -$23.4K – 15200
2023
Q4 		$23.4K Buy
2,467
+484
+24% +$3.57K ﹤0.01% 12492
2023
Q3 		$10.6K Buy
+1,983
New +$13.3K ﹤0.01% 13052
2023
Q1 		– Sell
-1,217
Closed -$8.76K – 15222
2022
Q4 		$8.76K Buy
+1,217
New +$10.9K ﹤0.01% 13733

Other funds holding NMTC

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Citadel Advisors's NMTC Position: Q2 2026 in Review

Citadel Advisors opened a new position in NeuroOne Medical Technologies (NMTC) in Q2 2026: 15,032 shares worth $45.7K. The stake represents ﹤0.01% of the portfolio and ranks #13164 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in NMTC as recently as Q4 2025.

Citadel Advisors first reported a position in NMTC in Q4 2022 and has held it in 7 quarters since. The position peaked at $183K in Q3 2025. 26 funds tracked by Wall St. Rank hold NMTC as of Q2 2026.

  • Citadel Advisors held 15,032 shares of NeuroOne Medical Technologies worth $45.7K as of Q2 2026.
  • NeuroOne Medical Technologies was a new Citadel Advisors position in Q2 2026.
  • NeuroOne Medical Technologies made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13164 holding.
  • Citadel Advisors first reported a position in NeuroOne Medical Technologies in Q4 2022 and has held it in 7 quarters since.
  • Citadel Advisors's NeuroOne Medical Technologies position peaked at $183K in Q3 2025.
  • 26 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.